MSMina Saeedi

Mina Saeedi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mina Saeedi has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design and Synthesis of Novel Biginelli Adducts: Anticancer Activity and In Silico Study

    by Aida Iraji, Sara Moghadam Farid, Mohammadreza Eftekharian, Paniz Naseri, Mohammad Mahdavi, Mina Saeedi, Tahmineh Akbarzadeh

    In this study, we report the synthesis of 14 Biginelli adducts and the evaluation of their anticancer activity against three human cancer cell lines: MCF‐7 (breast), SW480 (colon), and Hep‐G2 (liver), as well as the noncancerous Hek‐293 cell line. Among the synthesized derivatives, compound 8n emerged as the most potent, inducing significant cytotoxicity and apoptosis in MCF‐7 cells. Structure–activity relationship (SAR) analysis showed that specific modifications, such as methyl and nitro substitutions, enhanced anticancer activity, whereas bulky substituents reduced potency. Further investigations confirmed that compound 8n induces cell cycle arrest at the S and G2/M phases, highlighting its antiproliferative mechanism. Molecular docking and molecular dynamics simulations suggest that compound 8n could bind to Eg5, a potential regulator of cell division. However, this study did not include direct biochemical testing of the protein target (Eg5).

  • Triazole‐ and Imidazole‐Containing Compounds: Versatile VEGFR‐2 Inhibitors for Cancer Therapy

    by Parisa Nikfar, Mina Hosseini, Nima Rezaei, Mina Saeedi

    Vascular endothelial growth factor receptor 2 (VEGFR‐2) is a major mediator of pathological angiogenesis, which is critical to tumor progression and metastasis; therefore, inhibition of VEGFR‐2 remains a key therapeutic strategy for cancer. Despite the established clinical efficacy of several approved VEGFR‐2‐targeted agents, many first‐generation inhibitors are limited by dose‐limiting toxicities and the emergence of resistance, highlighting an ongoing need for next‐generation compounds with improved selectivity and more favorable safety profiles. Among nitrogen‐containing heterocyclic frameworks, triazoles and imidazoles are widely employed in medicinal chemistry owing to their favorable structural features, including appropriate stability, synthetic accessibility, and the ability to engage in key molecular interactions. This review summarizes recent advances in the design of triazole‐ and imidazole‐based VEGFR‐2 inhibitors, containing Schiff bases, bicyclic, tricyclic, and glycoside derivatives. We comparatively describe their VEGFR‐2 inhibitory activities and anticancer cytotoxicity data, and discuss key structure‐activity relationships and mechanistic insights, with particular emphasis on molecular features that appear to favor potent and selective VEGFR‐2 inhibition. This review compiles in vitro, in vivo, and in silico data on triazole‐ and imidazole‐based VEGFR‐2 inhibitors, providing a basis for understanding trends relevant to the design and development of optimized anti‐angiogenic agents.

  • Open Access

    Design, Synthesis, and Evaluation of New 1,4‐Naphthoquinone‐1,2,3‐triazoles as Antimalarial Agents

    by Lina Rezainia, Mohammad Hosein Sayahi, Eisa Kaveh Vernousfaderani, Seyedeh Sara Mirfazli, Mohammad Hossein Morshedsolouk, Navid Dastyafteh, Mehdi Nateghpour, Leila Farivar, Mina Saeedi, Haleh Hanifian, et al.

    The increasing resistance to existing antimalarial agents has prompted researchers to develop new therapeutic candidates. To address this, the hybridization of 1,4‐naphthoquinone and 1,2,3‐triazole yielded a new series of compounds evaluated as prospective in vitro antimalarial agents against the chloroquine‐sensitive 3D7 and chloroquine‐resistant K1 strains of Plasmodium falciparum . The target compounds were synthesized efficiently via a multistep route, involving the reaction of 1,4‐naphthoquinone and p ‐aminobenzoic acid, followed by reactions with propargylamine and different prepared chlorides. The synthetic route was concluded using a copper(I)‐catalyzed azide‐alkyne cycloaddition (CuAAC) “click” reaction. Based on structure‐activity relationships (SAR), the compound bearing a 4‐chloroaryl moiety ( 9g ) was the most active against P. falciparum 3D7, exhibiting 60.00% growth inhibition at 25 µM. Furthermore, compound 9k bearing a 2‐methylaryl moiety exhibited the most potent activity against P. falciparum K1, showing 64.52% growth inhibition at 50 µM. In silico simulations of compound 9g on thirteen protein targets in P. falciparum indicated strong interactions with the 1J3 and 1LDG targets. Also, the stability of the ligand‐protein complexes was verified for 3FGO.

  • Open Access

    Boswellia sacra Flueck. Oleo-gum-resin Nanophytosome: Development, Standardization, and Cholinesterase Inhibitory Potential

    by Mahnaz Mirimoghaddam, Mina Saeedi, Mohammad-Reza Delnavazi, Fatemeh Moraffah, Aida Iraji, Hamid Akbari Javar, Mahnaz Khanavi

    Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with cholinergic dysfunction. The limited efficacy of current acetylcholinesterase inhibitors underscores the need for novel therapeutic approaches. Objectives: This study evaluated the acetylcholinesterase inhibitory activity of Boswellia sacra extracts and their phytosomal formulations. Methods: The methanolic extract of B. sacra was fractionated using potassium hydroxide (KOH) and ethyl acetate to obtain a boswellic acid-enriched fraction, which was further purified by silica gel chromatography to yield two derivatives identified by 1H and 13C nuclear magnetic resonance (NMR) spectroscopy. A phytosomal formulation was prepared using soy lecithin and cholesterol via high-shear homogenization followed by ultrasonication. The optimized nanophytosome was characterized by dynamic light scattering (DLS), Fourier transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), transmission electron microscopy (TEM), and scanning electron microscopy (SEM). Entrapment efficiency, stability, the in vivo release profile, cholinesterase inhibitory activity was assessed using Ellman’s method. Results: Phytochemical analysis yielded 3-acetyl-11-keto-boswellic acid (1) and 11-keto-boswellic acid (2), and compound 1 was used for standardization. The optimized phytosome exhibited a mean particle size of 112 ± 12.28 nm, a polydispersity index (PDI) of 0.23 ± 0.1, a zeta potential of -53 ± 5.87 mV, and an entrapment efficiency of 75.3 ± 1.47%. FTIR and DSC confirmed molecular interactions between lecithin and the extract, whereas TEM and SEM revealed spherical morphology. The optimized phytosomal formulation demonstrated a gradual release profile, reaching 92% after 12 hours, and increased acetylcholinesterase inhibition to 61.0 ± 10.7% (half-maximal inhibitory concentration [IC50], 177.9 ± 26.8 µg/mL) compared with the non-formulated extract. It also showed moderate butyrylcholinesterase inhibition (42 - 48%) and selectivity for acetylcholinesterase inhibition. Conclusions: The optimized phytosomal formulation enhanced in vitro acetylcholinesterase inhibitory activity compared with the non-formulated extract, indicating the potential of this delivery system to improve the biological activity of Boswellia constituents in cell-free enzyme assays. However, these findings are preliminary and limited to in vitro experiments. Further studies are required to assess blood–brain barrier permeability, neuronal uptake, pharmacokinetics, and in vivo therapeutic efficacy.

  • Phytochemical analysis of Nepeta kotschyi Boiss. var. persica (Boiss.) Jamzad

    by Alaleh Riazatikesheh, Farid Dabaghian, Mina Saeedi, Mahnaz Khanavi

    Nepeta kotschyi var. persica (Boiss.) Jamzad is a member of the Lamiaceae family. Besides the many bioactive secondary metabolites, it has significant biological properties. However, the phytochemical profile of this species has yet to be comprehensively studied. Here, the ethyl acetate and methanol fractions of the hydroalcoholic extract (MeOH: 70%) of the plant’s aerial parts were subjected to phytochemical examination. Accordingly, 1,5,9-epideoxyloganic acid (1), luteolin (2), caffeic acid (3), rosmarinic acid (4), luteolin 7-O-glucoside (5), and nepetalinic acid (2-(1-carboxyethyl)-5-methylcyclopentane-1-carboxylic acid) (6) were isolated and characterized using NMR spectroscopy and specific rotation measurements.

  • Recent Advances on the α‐Glucosidase Inhibitory Activity of Benzimidazoles

    by Seyedeh Mana Shafiee, Mehdi Asadi, Mohammad Mahdavi, Mina Saeedi

    Benzimidazole derivatives have emerged as important scaffolds in the development of potent and effective α‐glucosidase inhibitors, key targets for managing type 2 diabetes mellitus (T2DM). This review highlights structural innovations and structure–activity relationships (SARs) of diverse benzimidazole‐based compounds, including hybrids with Schiff bases, thiosemicarbazones, 1,2,3‐triazoles, and oxadiazoles, all exhibiting α‐glucosidase inhibitory activity. Notably, numerous derivatives demonstrate superior inhibition compared to the standard reference drug, acarbose.


  • Design, Synthesis, Anticancer Properties, and Molecular Dynamics of New Quinazolinonethioacetohydrazide‐1,2,3‐Triazoles

    by Aida Iraji, Cambyz Irajie, Farnaz Nasouhi, Mina Saeedi, Tahmineh Akbarzadeh

    A novel series of quinazolinonethioacetohydrazide‐1,2,3‐triazole hybrids 13a–l was synthesized via a multi‐step process starting from isatoic anhydride, followed by the condensation reaction with carbon disulfide (CS 2 ), hydrazide formation, and the conduction of click chemistry reaction. Different spectroscopic techniques structurally characterized the synthesized compounds. The anticancer activity of the compounds was evaluated against MCF‐7 (breast) and SW480 (colon) cancer cell lines, while HEK 293 (normal cells) was used as a noncancerous control. Compound 13c exhibited the most potent and selective cytotoxicity, particularly against SW480 (IC 50 = 29.83 µM) and MCF‐7 (IC 50 = 17.32 µM) cancer cell lines, while demonstrating negligible toxicity toward normal HEK 293 cells. Cell cycle analysis indicated that 13c induced G2/M phase arrest and promoted apoptosis in MCF‐7 cells, as confirmed by annexin V/PI staining. In silico docking studies revealed strong binding of 13c to the vascular endothelial growth factor (VEGF) receptor, with key hydrogen bonding and π–π interactions at critical active‐site residues. In addition, 100 ns molecular dynamics simulations validated the stability of the VEGF– 13c complex and the persistence of binding interactions, supporting its role as a strong and stable VEGFR inhibitor.


  • Open Access

    Synthesis and evaluation of quinolinvinyl-phenoxy-1,2,3-triazole-acetamide hybrids against breast cancer

    by Maliheh Safavi, Aida Iraji, Sara Moghadam Farid, Mohammad Mahdavi, Samaneh Fattaheian-Dehkordi, Tahmineh Akbarzadeh, Mina Saeedi

    This work synthesized and evaluated a new series of quinolinvinyl-phenoxy-1,2,3-triazole-acetamide hybrids 9a-p against breast cancer cell lines, including MCF-7 and MDA-MB-231. Among 16 synthesized compounds, (E)-N-(4-chlorophenyl)-2-(4-((4-(2-(quinolin-2-yl)vinyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)acetamide (9f) was the most active compound on both cell lines, with IC50 values of 16.84 (MCF-7) and 21.78 µM (MDA-MB-231). 3D cell culture was also performed by providing an accurate in vitro model to test the most potent analog on the cancerous spheroids. Additionally, compound 9f demonstrated significant apoptosis induction in MDA-MB-231 cells, as evidenced by Annexin V-FITC/PI assays, with an increase in total apoptotic cells. Over-activation of caspase-3 was also observed in cell-based assays, indicating a potential apoptotic mechanism. DFT analysis revealed favorable electronic properties and electrostatic potential distributions that suggest these compounds’ high reactivity and binding affinity with biological targets. These results underscore the promising anticancer potential of the synthesized hybrids for further therapeutic applications.


  • Open Access

    Design and synthesis of new 1,2,3-triazole-methoxyphenyl-1,3,4-oxadiazole derivatives: selective butyrylcholinesterase inhibitors against Alzheimer’s disease

    by Aida Iraji, Roshanak Hariri, Mohammad Hashem Hashempur, Mahshad Ghasemi, Hormoz Pourtaher, Mina Saeedi, Tahmineh Akbarzadeh

    Alzheimer's disease (AD) remains a significant public health challenge due to its progressive cognitive impairment and the absence of proven treatments. In this study, several novel 1,2,3-triazole-methoxyphenyl-1,3,4-oxadiazole derivatives were synthesized and evaluated for their ability to inhibit key enzymes associated with AD: acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Structure-activity relationship (SAR) analysis revealed that derivatives featuring electron-withdrawing groups, particularly nitro and fluorine substituents, exhibited remarkable inhibitory activity against BChE while showing minimal effectiveness against AChE. Among these, compound 13s (R = 4-CH3, R' = 4-NO2) demonstrated the highest potency, selectively targeting BChE with an IC50 value of 11.01 µM. Molecular docking and molecular dynamics (MD) simulations provided deeper insights into the favorable interactions between these compounds and BChE. Additionally, cytotoxicity studies confirmed the active compound's limited toxicity toward normal cells, indicating a promising therapeutic profile. These findings suggest that the synthesized selective anti-BChE compounds hold potential for consideration in the later stages of AD treatment.


  • Open Access

    Synthesis, biological evaluation and molecular modeling studies of methyl indole-isoxazole carbohydrazide derivatives as multi-target anti-Alzheimer’s agents

    by Aida Iraji, Parisa Nikfar, Mohammad Nazari Montazer, Mona Karimi, Najmeh Edraki, Mina Saeedi, Seyedeh Sara Mirfazli

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects the elderly population globally and there is an urgent demand for developing novel anti-AD agents. In this study, a new series of indole-isoxazole carbohydrazides were designed and synthesized. The structure of all compounds was elucidated using spectroscopic methods including FTIR, 1H NMR, and 13C NMR as well as mass spectrometry and elemental analysis. All derivatives were screened for their acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activity. Out of all synthesized compounds, compound 5d exhibited the highest potency as AChE inhibitor with an IC50 value of 29.46 ± 0.31 µM. It showed significant selectivity towards AChE, with no notable inhibition against BuChE. A kinetic study on AChE for compound 5d indicated a competitive inhibition pattern. Also, 5d exhibited promising BACE1 inhibitory potential with an IC50 value of 2.85 ± 0.09 µM and in vitro metal chelating ability against Fe3+. The molecular dynamic studies of 5d against both AChE and BACE1 were executed to evaluate the behavior of this derivative in the binding site. The results showed that the new compounds deserve further chemical optimization to be considered potential anti-AD agents.